Table 3.
Mean cytokine levels by Stanford Health Assessment Questionnaire status among 42 postmenopausal breast cancer survivors after completion of primary therapy and prior to randomization in a dietary supplement intervention
| Cytokine (pg/mL) | All Participants | Previous Chemotherapy a | No Chemotherapy b | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||
| P-value | P-value | P-value | |||||||||||
|
|
|
|
|||||||||||
| n | Mean (SD) | Unadj.c | Adj.d | n | Mean (SD) | Unadj. c | Adj.d | n | Mean (SD) | Unadj.c | Adj.d | ||
| IL-6 e | SHAQ f= 0 | 31 | 0.45 (0.55) | 0.99 | 0.72 | 12 | 0.77 (0.60) | 0.35 | 0.45 | 19 | 0.24 (0.42) | 0.32 | 0.97 |
| SHAQ> 0 | 10 | 0.44 (0.61) | 3 | 0.40 (0.55) | 7 | 0.47 (0.68) | |||||||
| TNFR-2 g | SHAQ= 0 | 32 | 6166 (1254) | 0.11 | 0.13 | 12 | 6672 (1352) | 0.34 | 0.34 | 20 | 5863 (1116) | 0.16 | 0.40 |
| SHAQ> 0 | 10 | 7040 (2071) | 3 | 7578 (1793) | 7 | 6810 (2270) | |||||||
| IL-17 h | SHAQ= 0 | 31 | −0.94 (0.85) | 0.69 | 0.70 | 11 | −0.68 (0.67) | 0.34 | 0.37 | 20 | −1.07 (0.92) | 0.92 | 0.78 |
| SHAQ> 0 | 10 | −1.05 (0.54) | 3 | −1.09 (0.29) | 7 | −1.03 (0.63) | |||||||
a
Participants with history of chemotherapy prior to study enrollment
b
Participants without history of chemotherapy prior to study enrollment
c
two-sample t-test, unadjusted for body mass index
d
linear regression, adjusting for body mass index
e
IL-6, interleukin-6; log transformed due to skewness
f
SHAQ, Stanford Health Assessment Questionnaire
g
TNFR-2, tumor necrosis factor alpha receptor 2
h
IL-17, interleukin-17; log transformed due to skewness